Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
Date: May 20, 2019
Issue #:
1572Summary:
The FDA has approved emicizumab-kxwh (Hemlibra–
Genentech), a subcutaneously injected, factor IXa- and
X-directed antibody, for routine prophylaxis to
prevent or reduce bleeding episodes in patients with
hemophilia A. Emicizumab is not recommended for
treatment of bleeding.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Beriplex Eloctate emicizumab Hemlibra Hemophilia Source Type: research